UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga

Nucleic acid therapeutics, 2017-02, Vol.27 (1), p.1-3

2017

Volltextzugriff (PDF)

Therapeutic potential of Toll-like receptor 9 activation

Nature reviews. Drug discovery, 2006-06, Vol.5 (6), p.471-484

Krieg, Arthur M

2006

Volltextzugriff (PDF)

Exon skipping therapy for Duchenne muscular dystrophy

Advanced drug delivery reviews, 2015-06, Vol.87, p.104-107

2015

Volltextzugriff (PDF)

Development of TLR9 agonists for cancer therapy

The Journal of clinical investigation, 2007-05, Vol.117 (5), p.1184-1194

Krieg, Arthur M

2007

Volltextzugriff (PDF)

CpG still rocks! Update on an accidental drug

Nucleic acid therapeutics, 2012-04, Vol.22 (2), p.77

Krieg, Arthur M

2012

Volltextzugriff (PDF)

Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists

Advanced drug delivery reviews, 2009-03, Vol.61 (3), p.195-204

2009

Volltextzugriff (PDF)

Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity

Immunological reviews, 2007-12, Vol.220 (1), p.251-269

2007

Volltextzugriff (PDF)

CPG MOTIFS IN BACTERIAL DNA AND THEIR IMMUNE EFFECTS

Annual review of immunology, 2002-01, Vol.20 (1), p.709-760

Krieg, Arthur M

2002

Volltextzugriff (PDF)

Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization

The Journal of immunology (1950), 2020-03, Vol.204 (5), p.1386-1394

2020

Volltextzugriff (PDF)

CpG motifs: the active ingredient in bacterial extracts?

Nature medicine, 2003-07, Vol.9 (7), p.831-835

Krieg, Arthur M

2003

Volltextzugriff (PDF)

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

Cancer discovery, 2021-12, Vol.11 (12), p.2998-3007

2021

Volltextzugriff (PDF)

Rigging Innate Immunity against the Flu

Molecular therapy, 2017-09, Vol.25 (9), p.1993-1994

Krieg, Arthur M.

2017

Volltextzugriff (PDF)

CpG Still Rocks! Update on an Accidental Drug

Nucleic acid therapeutics, 2012-04, Vol.22 (2), p.77-89

Krieg, Arthur M.

2012

Volltextzugriff (PDF)

Is RNAi Dead?

Molecular therapy, 2011-06, Vol.19 (6), p.1001-1002

Krieg, Arthur M

2011

Volltextzugriff (PDF)

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities

European journal of immunology, 2004-01, Vol.34 (1), p.251-262

2004

Volltextzugriff (PDF)

Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells

The Journal of immunology (1950), 2000-01, Vol.164 (2), p.944-953

2000

Volltextzugriff (PDF)

Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides

Nucleic acid therapeutics, 2023-02, Vol.33 (1), p.1-16

2023

Volltextzugriff (PDF)

Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8

The Journal of experimental medicine, 2005-12, Vol.202 (11), p.1575-1585

2005

Volltextzugriff (PDF)

Identification of RNA Sequence Motifs Stimulating Sequence-Specific TLR8-Dependent Immune Responses

The Journal of immunology (1950), 2008-03, Vol.180 (6), p.3729-3738

2008

Volltextzugriff (PDF)

Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848

Nature immunology, 2002-06, Vol.3 (6), p.499-499

2002

Volltextzugriff (PDF)

Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls

Nucleic acid therapeutics, 2019-06, Vol.29 (3), p.115-115

2019

Volltextzugriff (PDF)

Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides

Current oncology reports, 2004-03, Vol.6 (2), p.88-95

Krieg, Arthur M

2004

Volltextzugriff (PDF)

Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery

Proceedings of the National Academy of Sciences - PNAS, 2012-04, Vol.109 (14), p.5150-5151

2012

Volltextzugriff (PDF)

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2008-08, Vol.26 (24), p.3979-3986

2008

Volltextzugriff (PDF)

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909

The Journal of clinical investigation, 2005-03, Vol.115 (3), p.739-746

2005

Volltextzugriff (PDF)

1 – 25 von 392

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(325)
Mit Volltextzugriff
(333)

Publikationsform

Sprache

Englisch
(390)
Japanisch
(68)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(262)
Life Sciences & Biomedicine
(250)
Animals
(170)
Immunology
(132)
Mice
(128)
Humans
(121)
Biological And Medical Sciences
(78)
Female
(73)
Oligodeoxyribonucleotides - Pharmacology
(61)
Medicine, Research & Experimental
(53)
Research & Experimental Medicine
(53)
Medical Sciences
(50)
Cpg Islands - Immunology
(48)
Adjuvants, Immunologic - Pharmacology
(47)
Biochemistry & Molecular Biology
(44)
Mice, Inbred Balb C
(42)
Oligodeoxyribonucleotides - Immunology
(38)
Base Sequence
(37)
Male
(37)
Mice, Inbred C57bl
(37)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga

Therapeutic potential of Toll-like receptor 9 activation

Exon skipping therapy for Duchenne muscular dystrophy

Development of TLR9 agonists for cancer therapy

CpG still rocks! Update on an accidental drug

Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists

Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity

CPG MOTIFS IN BACTERIAL DNA AND THEIR IMMUNE EFFECTS

Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization

CpG motifs: the active ingredient in bacterial extracts?

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

Rigging Innate Immunity against the Flu

CpG Still Rocks! Update on an Accidental Drug

Is RNAi Dead?

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities

Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells

Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides

Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8

Identification of RNA Sequence Motifs Stimulating Sequence-Specific TLR8-Dependent Immune Responses

Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848

Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls

Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides

Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909

Suchergebnisse filtern